Rheumatology Therapeutics Market Overview, Growth Impact and Demand by Regions till 2026
Rheumatology
diseases affects the supporting or connecting structures of the body
mostly joints, ligaments, muscles, tendons, and rarely some organs of
the body. This disease is characterized by inflammation of joints and
it affects spine in some types of rheumatology disease. There are
more than 100 types of rheumatic disease. It is caused by various
genetic and environmental factors, such as unhealthy diet and
changing lifestyle, which can lead to rheumatology diseases.
Osteoarthritis, ankylosing spondylitis, rheumatoid arthritis, gout,
psoriatic arthritis, reactive arthritis, fibromyalgia, and
scleroderma are some of the common types of rheumatology diseases.
Rheumatology treatment involves medications, exercises, and physical
therapies with surgical treatment to cure joint damage. Early
treatment can be beneficial for treatment of rheumatologic symptoms.
Physicians prescribe disease-modifying antirheumatic drugs (DMARD’s)
for the treatment of rheumatologic disease. Sufficient nutrition,
proper exercise, and medications can help to cure rheumatology
diseases.
Increasing burden
of rheumatology diseases globally is propelling the growth of
rheumatology therapeutics market
The increase in
population with some sort of rheumatology arthritis globally is major
driving factor for the rheumatology therapeutics market. According to
data given by Centers for Disease Control and Prevention (CDC) in
2013, around 52.5 million of adults in the U.S. have suffered from
rheumatology arthritis, which equals to 23% of the population with 1%
being the prevalence rate of rheumatology diseases globally.
According to the Global Burden of Disease 2010 study data, prevalence
rate for knee arthritis globally was 3.8% and for hip osteoarthritis
was 0.85% globally. Additionally, technological advancements in
medical field, investments in the healthcare sector over research and
development, and rising trend of fitness are important factors
contributing to the growth of rheumatology therapeutics market.
According to the World Health Organization (WHO) in 2014, government
spent 15.5% on healthcare sector.
However,
introduction of biosimilars is major restraint for rheumatology
therapeutics market. Increasing demand for biosimilar may hinder the
conventional drug commonly used for rheumatology diseases treatment.
Patent expiry of some drugs used in the treatment of rheumatology
diseases is also hampering the growth of rheumatology therapeutics
market. For instance, patent expiry of Enbrels drug in 2012.
Rheumatoid
arthritis holds the largest share due to high prevalence rate in the
rheumatology therapeutics market
The global
rheumatology therapeutics market is segmented by disease type, by
drug type, by end user, and by region
On the basis of
disease type, the rheumatology therapeutics market is segmented into:
Osteoarthritis
Ankylosing
spondylitis
Rheumatoid
arthritis
Gout
Psoriatic
arthritis
Reactive
arthritis
Fibromyalgia
Scleroderma
Others
On the basis of drug
type, the rheumatology therapeutics market is segmented into:
Disease
Modifying Antirheumatic Drugs (DMAD’s)
Humira
Remicade
Cyclosporine
Methotrexate
Biologics
Tofacitinib
Others
On the basis of end
user, the rheumatology therapeutics market is segmented into:
Hospitals
Medical clinics
Inquire Here
Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/796
Established
healthcare sector of North America is contributing to the leading
position of this region in rheumatology therapeutics market
Regional
segmentation of rheumatology therapeutics market by Coherent Market
Insights comprises of North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America dominates
rheumatology therapeutics market, owing to increasing population with
rheumatology diseases, changing lifestyle, and established medical
and healthcare sector. According to Centers for Disease Control and
Prevention (CDC), around 27 million people are suffering with
Clinical arthritis in the U.S, around 8 million people with Gout
syndrome, and 78 million adults are at risk to suffer from clinical
arthritis till 2040. Asia Pacific is expected to witness the growth
in the rheumatology therapeutics market due to increase in patient
population and developing healthcare sector.
The key players
are involved in doing licensing agreement with other manufacturers to
hold the major market share in rheumatology therapeutics market
Key industry players
operating the rheumatology therapeutics market includes AstraZeneca,
Rigel pharma, Abbott Laboratories, Pfizer, Amgen, Janssen Biotech,
Merck Co. Inc., Eli Lily, and Alder Biopharmaceuticals. Key players
are involved in the acquisitions and agreement with other companies
to hold the maximum share. For instance, licensing agreement of Bri
Stol-Myers Squibb with Alder Biopharmaceuticals Company and the major
acquisition of Ardea Biosciences by AstraZeneca are one of the
important agreements between 2007 and 2012.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment